Abstract
Sepsis is an acute and severe disease associated with early and late high mortality, high and growing prevalence, and impressive costs. In October 2002, during the European Society of Intensive Care Medicine annual congress, the Surviving Sepsis Campaign was launched through a "Barcelona Declaration" - a document calling critical care providers, governments, health agencies and lay people to join the fight against sepsis. The aim of the campaign was to reduce the sepsis mortality rate by 25% within 5 years (actually, this deadline has been ended from 2007 to 2009). In 2003, a group of international critical care and infectious disease experts in the diagnosis and management of infection and sepsis met to develop guidelines that the bedside clinician could use to improve the outcome of severe sepsis and septic shock. A comprehensive document created from the committees deliberations was published in prestigious journals. Thus, the SSC is a global, multi-organizational initiative to fight sepsis and undoubtedly, this campaign is a historic step for critical care medicine. This paper highlights the recommendations and the strategies proposed by SSC to implement them in intensive care units.
Keywords: septic shock, Vasopressors, Recombinant Human Activated Protein, Sepsis Campaign screening, Inotropic Therapy, Steroids
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title: Surviving Sepsis Campaign: A Project to Change Sepsis Trajectory
Volume: 6 Issue: 2
Author(s): Eliezer Silva, Nelson Akamine, Reinaldo Salomao, Sean R. Townsend, Richard P. Dellinger and Mitchell Levy
Affiliation:
Keywords: septic shock, Vasopressors, Recombinant Human Activated Protein, Sepsis Campaign screening, Inotropic Therapy, Steroids
Abstract: Sepsis is an acute and severe disease associated with early and late high mortality, high and growing prevalence, and impressive costs. In October 2002, during the European Society of Intensive Care Medicine annual congress, the Surviving Sepsis Campaign was launched through a "Barcelona Declaration" - a document calling critical care providers, governments, health agencies and lay people to join the fight against sepsis. The aim of the campaign was to reduce the sepsis mortality rate by 25% within 5 years (actually, this deadline has been ended from 2007 to 2009). In 2003, a group of international critical care and infectious disease experts in the diagnosis and management of infection and sepsis met to develop guidelines that the bedside clinician could use to improve the outcome of severe sepsis and septic shock. A comprehensive document created from the committees deliberations was published in prestigious journals. Thus, the SSC is a global, multi-organizational initiative to fight sepsis and undoubtedly, this campaign is a historic step for critical care medicine. This paper highlights the recommendations and the strategies proposed by SSC to implement them in intensive care units.
Export Options
About this article
Cite this article as:
Silva Eliezer, Akamine Nelson, Salomao Reinaldo, Townsend R. Sean, Dellinger P. Richard and Levy Mitchell, Surviving Sepsis Campaign: A Project to Change Sepsis Trajectory, Endocrine, Metabolic & Immune Disorders - Drug Targets 2006; 6 (2) . https://dx.doi.org/10.2174/187153006777442378
DOI https://dx.doi.org/10.2174/187153006777442378 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Ruthenium as an Effective Nitric Oxide Scavenger
Current Topics in Medicinal Chemistry Echocardiographic Hemodynamic Monitoring in the Critically Ill Patient
Current Cardiology Reviews Drotrecogin Alfa (Activated) in the Treatment of Severe Sepsis
Current Drug Safety Targeting the Noradrenergic System in Posttraumatic Stress Disorder: A Systematic Review and Meta-Analysis of Prazosin Trials
Current Drug Targets Oxytocin in the Heart Regeneration
Recent Patents on Cardiovascular Drug Discovery The Current Status and Future Perspectives of Studies of Cannabinoid Receptor 1 Antagonists as Anti-Obesity Agents
Current Topics in Medicinal Chemistry Diabetes and Nutritional Screening in Post-Bariatric Patients
Current Diabetes Reviews Cardiovascular Side Effects of New Antidepressants and Antipsychotics: New Drugs, old Concerns?
Current Pharmaceutical Design Preface
Current Topics in Medicinal Chemistry Blood Pressure Variability/Dipper/Non-dipper in Hypertension and Diabetes
Current Hypertension Reviews Recombinant Immunotoxins for the Treatment of Chemoresistant Hematologic Malignancies
Current Pharmaceutical Design Safety of Inhaled Corticosteroids. Why the Variation in Systemic Adverse Effects?
Current Pediatric Reviews A Catalytically Inactive Lys49 PLA2 Isoform from Bothrops jararacussu venom that Stimulates Insulin Secretion in Pancreatic Beta Cells
Protein & Peptide Letters Chiral Kinase Inhibitors
Current Topics in Medicinal Chemistry Cytotoxic and Allergenic Potential of Bioactive Proteins and Peptides
Current Pharmaceutical Design New Mucoadhesive Polymeric Film for Ophthalmic Administration of Acetazolamide
Recent Patents on Drug Delivery & Formulation Medicinal Properties of the Jamaican Pepper Plant Pimenta dioica and Allspice
Current Drug Targets Buprenorphine-Mediated Transition from Opioid Agonist to Antagonist Treatment: State of the Art and New Perspectives
Current Drug Abuse Reviews Recent Trends in Development of Fermented Milks
Current Nutrition & Food Science Design and Synthesis of Dopaminergic Agonists
Current Medicinal Chemistry